Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study
Abstract
Abstract This prespecified AZALEA-TIMI 71 analysis showed that prior oral anticoagulation (OAC) experience indicates bleeding risk in atrial fibrillation. The factor XI inhibitor abelacimab reduced bleeding regardless of prior OAC experience, with potentially greater absolute benefit among OAC-naïve patients. This trial was registered at www.ClinicalTrials.gov as NCT04755283.
Article Details
Authors (16)
Andre M. Small
1Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Siddharth M. Patel
TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA.
Robert P. Giugliano
David A. Morrow
Erica L. Goodrich
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston
Bruce Hug
Sanobar Parkar
Shih-Ann Chen
Shaun G. Goodman
St. Michael’s Hospital, Unity Health Toronto, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada (S.G.G.).
Boyoung Joung
Yonsei University, Seoul, Korea (the Republic of)
Robert G. Kiss
Department of Cardiology, Central Hospital of Northern Pest-Military Hospital, Heart and Vascular Center, Semmelweis University, Budapest, Hungary (R.G.K.).
Wojciech Wojakowski
Jeffrey I. Weitz
Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, Canada (J.I.W.).
Dan Bloomfield
Marc S. Sabatine
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston
Christian T. Ruff